Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis

Barbara Cannella, Anne H. Cross, Cedric S. Raine

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Based on previous observations showing that inflammatory episodes in the central nervous system (CNS) of SJL/J mice with adoptively transferred experimental allergic encephalomyelitis (EAE) are associated with a concomitant upregulation of adhesion-related molecules around CNS blood vessels, the present study was undertaken to block the development of EAE with injections of monoclonal antibodies (mAbs) to two different adhesion molecules. The mAbs selected were directed against intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) and were administered at different doses (50 μg-1 mg), as single and multiple injections, and at various time points post-transfer of myelin basic protein-specific lymphocytes. Although one group of EAE mice given αFLA-1 displayed adverse effects after treatment, on the whole, neither mAb had a statistically significant effect on the outcome of EAE in this murine model. There was, however, down-regulation in the CNS of the respective adhesion molecules after treatment. Whether the lack of beneficial effect was related to the stage of EAE at which the mAbs were administered, remains to be proven. This is the first report suggesting that αICAM-1 and αLFA-1 mAbs might have opposite effects (i.e. ameliorating or worsening) upon murine EAE and the different effect of αLFA-1 might be related to this molecule being involved in more cell signaling mechanisms than ICAM-1.

Original languageEnglish (US)
Pages (from-to)43-55
Number of pages13
JournalJournal of Neuroimmunology
Volume46
Issue number1-2
DOIs
StatePublished - 1993

Fingerprint

Autoimmune Experimental Encephalomyelitis
Lymphocyte Function-Associated Antigen-1
Intercellular Adhesion Molecule-1
Monoclonal Antibodies
Central Nervous System
Therapeutics
Injections
Myelin Basic Protein
Blood Vessels
Up-Regulation
Down-Regulation
Lymphocytes

Keywords

  • Adhesion molecules
  • Autoimmunity
  • Demyelination
  • Treatment

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Clinical Neurology
  • Neurology

Cite this

Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis. / Cannella, Barbara; Cross, Anne H.; Raine, Cedric S.

In: Journal of Neuroimmunology, Vol. 46, No. 1-2, 1993, p. 43-55.

Research output: Contribution to journalArticle

Cannella, Barbara ; Cross, Anne H. ; Raine, Cedric S. / Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis. In: Journal of Neuroimmunology. 1993 ; Vol. 46, No. 1-2. pp. 43-55.
@article{22b3c765e1f14e6da4dd861e6db98674,
title = "Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis",
abstract = "Based on previous observations showing that inflammatory episodes in the central nervous system (CNS) of SJL/J mice with adoptively transferred experimental allergic encephalomyelitis (EAE) are associated with a concomitant upregulation of adhesion-related molecules around CNS blood vessels, the present study was undertaken to block the development of EAE with injections of monoclonal antibodies (mAbs) to two different adhesion molecules. The mAbs selected were directed against intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) and were administered at different doses (50 μg-1 mg), as single and multiple injections, and at various time points post-transfer of myelin basic protein-specific lymphocytes. Although one group of EAE mice given αFLA-1 displayed adverse effects after treatment, on the whole, neither mAb had a statistically significant effect on the outcome of EAE in this murine model. There was, however, down-regulation in the CNS of the respective adhesion molecules after treatment. Whether the lack of beneficial effect was related to the stage of EAE at which the mAbs were administered, remains to be proven. This is the first report suggesting that αICAM-1 and αLFA-1 mAbs might have opposite effects (i.e. ameliorating or worsening) upon murine EAE and the different effect of αLFA-1 might be related to this molecule being involved in more cell signaling mechanisms than ICAM-1.",
keywords = "Adhesion molecules, Autoimmunity, Demyelination, Treatment",
author = "Barbara Cannella and Cross, {Anne H.} and Raine, {Cedric S.}",
year = "1993",
doi = "10.1016/0165-5728(93)90232-N",
language = "English (US)",
volume = "46",
pages = "43--55",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis

AU - Cannella, Barbara

AU - Cross, Anne H.

AU - Raine, Cedric S.

PY - 1993

Y1 - 1993

N2 - Based on previous observations showing that inflammatory episodes in the central nervous system (CNS) of SJL/J mice with adoptively transferred experimental allergic encephalomyelitis (EAE) are associated with a concomitant upregulation of adhesion-related molecules around CNS blood vessels, the present study was undertaken to block the development of EAE with injections of monoclonal antibodies (mAbs) to two different adhesion molecules. The mAbs selected were directed against intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) and were administered at different doses (50 μg-1 mg), as single and multiple injections, and at various time points post-transfer of myelin basic protein-specific lymphocytes. Although one group of EAE mice given αFLA-1 displayed adverse effects after treatment, on the whole, neither mAb had a statistically significant effect on the outcome of EAE in this murine model. There was, however, down-regulation in the CNS of the respective adhesion molecules after treatment. Whether the lack of beneficial effect was related to the stage of EAE at which the mAbs were administered, remains to be proven. This is the first report suggesting that αICAM-1 and αLFA-1 mAbs might have opposite effects (i.e. ameliorating or worsening) upon murine EAE and the different effect of αLFA-1 might be related to this molecule being involved in more cell signaling mechanisms than ICAM-1.

AB - Based on previous observations showing that inflammatory episodes in the central nervous system (CNS) of SJL/J mice with adoptively transferred experimental allergic encephalomyelitis (EAE) are associated with a concomitant upregulation of adhesion-related molecules around CNS blood vessels, the present study was undertaken to block the development of EAE with injections of monoclonal antibodies (mAbs) to two different adhesion molecules. The mAbs selected were directed against intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) and were administered at different doses (50 μg-1 mg), as single and multiple injections, and at various time points post-transfer of myelin basic protein-specific lymphocytes. Although one group of EAE mice given αFLA-1 displayed adverse effects after treatment, on the whole, neither mAb had a statistically significant effect on the outcome of EAE in this murine model. There was, however, down-regulation in the CNS of the respective adhesion molecules after treatment. Whether the lack of beneficial effect was related to the stage of EAE at which the mAbs were administered, remains to be proven. This is the first report suggesting that αICAM-1 and αLFA-1 mAbs might have opposite effects (i.e. ameliorating or worsening) upon murine EAE and the different effect of αLFA-1 might be related to this molecule being involved in more cell signaling mechanisms than ICAM-1.

KW - Adhesion molecules

KW - Autoimmunity

KW - Demyelination

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0027448726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027448726&partnerID=8YFLogxK

U2 - 10.1016/0165-5728(93)90232-N

DO - 10.1016/0165-5728(93)90232-N

M3 - Article

C2 - 8103061

AN - SCOPUS:0027448726

VL - 46

SP - 43

EP - 55

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -